| atezolizumab based treatment |
| atezolizumab plus carboplatin plus nab-paclitaxel | atezolizumab plus nab-paclitaxel | atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide | atezolizumab plus paclitaxel |
es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA) | | | | |
es-BC - TNBC - NA - all population 5 | | | | |
es-BC - TNBC - NA - PDL1 positive 1 | | | | |
es-BC - Triple negatif (TNBC) - 1st line (L1) | | | | |
mBC - Triple negative (TNBC) - (neo)adjuvant (NA) | | | | |
mBC - Triple negative (TNBC) - 1st Line (L1) 1 | | | | |
mBC - TNBC - L1 - all population 7 | | | | |
mBC - TNBC - L1 - PDL1 positive 4 | | | | |
mBC-Triple negative (TNBC) - 2nd Line (L2) 3 | | | | |
mBC - TNBC - L2 - all population 2 | | | | |
mBC - TNBC - L2 - PDL1 positive 2 | | | | |